Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
After obtaining approval from the Institutional Review Board of our institution, written informed consent is obtained from patients undergoing cardiac surgery are enrolled in this prospective study and randomly allocated into one of two groups: Group-C (n=15) and Group-HES (n=15).
All recruited patients will be given patient identification number (PIN) for the present study of 01-30 according to their order of interview and recruitment. Investigators will prepare 15 yellow and 15 green cards, which will be inserted in 30 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (Envelop number). After printing the envelope number outside envelope, all sealed envelopes with cards will be conveyed to and kept in pharmacy department.
According to the color of the card, attending anesthesiologists will give crystalloid for yellow card or HES for green cards, respectively, to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture.
Patient data and statistical analyses:
Patient's data whole blood viscosity, PaO2, FiO2, Hemoglobin, urine amount, s-glucose will be determined from the patients' medical record after patient's discharge.
All statistical analyses will be performed after the 30th patient's discharge and data acquisition
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intravenous Crystalloid | Placebo Comparator | crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture |
|
| Intravenous HES | Active Comparator | HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intravenous Crystalloid | Drug | crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture |
|
| Measure | Description | Time Frame |
|---|---|---|
| whole blood viscosity | with 1 hour after the completion of procedure |
| Measure | Description | Time Frame |
|---|---|---|
| PaO2/FiO2 ratio | PaO2/FiO2 ratio measured by arterial blood gas analysis | with 1 hour after the completion of procedure |
| hematocrit | serum hematocrit, % |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tae-Yop Kim, MD, PhD | Contact | 82-2-2030-5448 | taeyop@gmail.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intravenous HES | Drug | HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture |
|
| with 1 hour after the completion of procedure |
| glucose | serum glucose level, g/dl | with 1 hour after the completion of procedure |
| osmolarity | serum osmolarity, mOsm | with 1 hour after the completion of procedure |
| urine output | hourly urine output, ml/hr | with 1 hour after the completion of procedure |
| Maximum clot formation | Maximum clot formation in rotational thromboelastometry (ROTEM) analysis, mm | with 1 hour after the completion of procedure |